MedTrace Logo

Tobramycin Tear Concentrations

NCT00695435 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2010-03-02

Study results available
· View outcomes & findings →

Summary

To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic Solution in normal volunteers.

Conditions

  • Dry Eye

Interventions

DRUG

TOBRADEX Ophthalmic Suspension

TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline

DRUG

Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension

Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline

DRUG

TOBREX Ophthalmic Solution

TOBREX Ophthalmic Solution 1 drop each eye at baseline

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00695435 on ClinicalTrials.gov